Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039618 | 0.83 | NPC1 (0.41) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL16321464 | 0.81 | PLA2G7 (0.32) | — | |
| SCHEMBL10974043 | 0.80 | NPC1 (0.46) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL10973763 | 0.77 | NPC1 (0.61) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL10972004 | 0.77 | NPC1 (0.35) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL13823454 | 0.77 | NPC1 (0.35) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL28969730 | 0.76 | EPHX1 (0.33) | — | |
| SCHEMBL10972981 | 0.75 | NPC1 (0.51) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL10970812 | 0.75 | NPC1 (0.42) | NPC1RAB9ACASP3SENP8NLRP3 | |
| SCHEMBL3363996 | 0.74 | NPC1 (0.33) | NPC1RAB9ACASP3SENP8NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-7351720-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1608612-B1 | PROCESS FOR PRODUCING CYCLOHEXENONE LONG-CHAIN ALCOHOLS | MEIJI DAIRIES CORP (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7235700-B2 | cyclohexenone long-chain alcohol has a low molecular weight and is known to be useful as a prophylactic or therapeutic drug for cerebral diseases such as dementia | MEIJI DAIRIES CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| US-20060135818-A1 | Process for producing cyclohexenone long-chain alcohols | MEIJI DAIRIES CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1608612-A1 | PROCESS FOR PRODUCING CYCLOHEXENONE LONG-CHAIN ALCOHOLS | Meiji Dairies Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087630-A1 | PROCESS FOR PRODUCING CYCLOHEXENONE LONG-CHAIN ALCOHOLS | MEIJI DAIRIES CORPORATION (JP) | 2004-10-14 | — | — | WO | disclosed |
| US-4546104-A | Pyrazolopyridine cycloalkanones and process for their preparation | ICI AMERICAS INC. (US) | 1985-10-08 | — | — | US | disclosed |
| EP-0141608-A2 | Pyrazolopyridine cycloalkanone derivatives | ICI AMERICAS INC. (US) | 1985-05-15 | — | — | EP | disclosed |
| US-4391827-A | 3-(2-Hydroxy-4-(substituted)phenyl)-cycloalkanone and cycloalkanol analgesic agents and intermediates therefor | PFIZER INC. (US) | 1983-07-05 | — | — | US | disclosed |
| US-4306097-A | 3-[2-Hydroxy-4-(substituted)phenyl]-cycloalkanol analgesic agents | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135818-A1 | Process for producing cyclohexenone long-chain alcohols | ADH1C, ADH1A, HACD2 | NPC1 2446/4885RAB9A 4300/4885CASP3 1670/4885 |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ACKR3, CCR7, CCR2 | NPC1 505/4885RAB9A 785/4885CASP3 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.